Hemcheck Sweden AB has signed an exclusive distribution agreement with Advanced Technology Company K.S.C.P. (“ATC”), one of the leading distributors of medical equipment in Kuwait. The agreement will be in force from Feb 1st and valid until the end of Dec 2023, concerning the Kuwaiti market. ATC has with the agreement committed to an initial purchase order of readers and one-time tests.
– ATC is a well reputed and leading distributor in the Kuwaiti market, and they have shown a lot of interest in Hemcheck and the potential of our products. We believe this is a very good first step into the GCC region and we look forward to working with ATC and hope that it will be a successful and long-term collaboration, says Joen Averstad, CEO of Hemcheck.
– We are very pleased that we have signed this agreement with Hemcheck. Their products fit well into our portfolio and we have a very positive view that customers will implement these products in our market. We very much look forward to the collaboration, says Mahmoud Chehime, Director, Specialty Diagnostics & Laboratory Solutions of ATC.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
ATC was founded in 1981 and has established itself as the leading end-to-end total healthcare and environmental solutions provider capable of delivering over 95% of a hospital’s diverse requirements. ATC has a leading market share and is currently serving over 1,000 customers in the Kuwait market including government and private hospitals, dental practitioners, laboratories and physicians. ATC generates yearly revenues of around KD 150 million and employs over 2,100 people. The Company has been listed on the Kuwait Stock Exchange since 2007.
Read more at https://www.atc.com.kw/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on January 28, 2021 at 12.05